insights_auto
Pse është rritur NSIS-B 2,00%?
Zhytu më thellëchevron_right
NSIS-B:CPH
Novozymes A/S
458,00Â DKK
arrow_upward
+2,00%(+9,00) 1D
15 tet, 5:00:00 m.d., GMT+2 · DKK
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për NSIS-B...
Hap
454,10Â DKK
I lartë
461,80Â DKK
I ulët
452,40Â DKK
Kapitalizimi i tregut
183,47Â mld
Vëllimi mesatar
583,65 mijë
Vëllimi
0,00
Maksimumi 52-javor
465,00Â DKK
Minimumi 52-javor
336,80Â DKK
Aksionet në qarkullim
414,56Â mln
Numri i punonjësve
11 mijë
Hap
454,10Â DKK
I lartë
461,80Â DKK
I ulët
452,40Â DKK
Kapitalizimi i tregut
183,47Â mld
Vëllimi mesatar
583,65 mijë
Vëllimi
0,00
Maksimumi 52-javor
465,00Â DKK
Minimumi 52-javor
336,80Â DKK
Aksionet në qarkullim
414,56Â mln
Numri i punonjësve
11 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
14 orë më parë
Novonesis stock stands 1.27 percent below its 52-week high
Profili
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
Rreth Novozymes A/S
Drejtori ekzekutivEster Baiget
Punonjësit11,1 mijë
Themeluar më2000
Selia-
SektoriSpeciality chemicals
Uebsajtinovonesis.com